Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Hello Phantom, you said you had a call for next week where you may be able to ask some questions.
I guess Q1/Q2 means AML adjuvant data by end of June 2022, (and maybe some more active arm data)??

The PR said "Three patients were treated with MT-401 using the legacy reagent and three additional patients were treated with MT 401 using the new reagent."
If you think it would be meaningful, can you ask if the MRD+ to MRD- patient got the "legacy" or "new" reagent?

But mainly, we need clarification on one major issue from the PR.

We know they said "but beginning any additional clinical trial is subject to the receipt of additional funding".

OK, we KNOW that that applies to ALL of the following:
Off-the-shelf (OTS) product candidates.
The Company expects to expand OTS clinical trials in other hematological malignancies and solid tumors
Preclinical / development activities
Analyzing potential of a 12-antigen product
Assessing potential of combination therapies for MT-401 and MT-601

BUT, does the sentence "but beginning any additional clinical trial is subject to the receipt of but beginning any additional clinical trial is subject to the receipt of additional funding", ALSO apply to the Pancreatic and Lymphoma that they said they were starting?

OR do those 2 trials NOT go forward without "the receipt of additional funding" ??

Thank You